Conclusions:
Many questions remain as to how best to predict the onset of aCFLD. It
is unlikely a single test will reliably detect or diagnose CFHBI, but
rather a combination of tests with an algorithmic approach (e.g. blood
tests + radiological studies) relying on changes over time rather than
strict cut-offs. Elastography methods are currently gaining rapid
momentum and soon will likely be incorporated in routine clinical
settings. Future methods also include the incorporation of newer
biomarkers and other upcoming modalities such as multi-omics, and
artificial intelligence (AI)-driven protocols38,70,76.
Table 1 – Summary of non-invasive tests utilized in cystic
fibrosis-related hepatobiliary involvement